Difficulty: Medium
Average Score: 89%
Practice
The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is
Correct answer
C
Rationale
In this question, the correct answer is C) Selegiline. Selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B) enzyme. MAO-B is responsible for the breakdown of dopamine in the brain. By inhibiting this enzyme, selegiline increases dopamine levels in the brain, which helps in managing symptoms of Parkinson's disease.
Option A) Carbidopa is incorrect because it doesn't directly inhibit the degradation of dopamine. Carbidopa is often used in combination with levodopa to prevent its peripheral conversion to dopamine and enhance its central effects.
Option B) Amantadine is incorrect because it mainly works by increasing dopamine release from nerve endings and also has NMDA receptor antagonist properties. It does not inhibit dopamine degradation.
Option D) Bromocriptine is incorrect because it is a dopamine agonist that directly stimulates dopamine receptors in the brain, rather than inhibiting dopamine degradation.
Understanding how different antiparkinsonian drugs work is crucial for healthcare professionals to make informed decisions when treating patients with Parkinson's disease. Knowing the mechanisms of action of these drugs helps in tailoring treatment plans to individual patient needs and optimizing therapeutic outcomes.
Option A) Carbidopa is incorrect because it doesn't directly inhibit the degradation of dopamine. Carbidopa is often used in combination with levodopa to prevent its peripheral conversion to dopamine and enhance its central effects.
Option B) Amantadine is incorrect because it mainly works by increasing dopamine release from nerve endings and also has NMDA receptor antagonist properties. It does not inhibit dopamine degradation.
Option D) Bromocriptine is incorrect because it is a dopamine agonist that directly stimulates dopamine receptors in the brain, rather than inhibiting dopamine degradation.
Understanding how different antiparkinsonian drugs work is crucial for healthcare professionals to make informed decisions when treating patients with Parkinson's disease. Knowing the mechanisms of action of these drugs helps in tailoring treatment plans to individual patient needs and optimizing therapeutic outcomes.